Matinas BioPharma Holdings Inc. (MTNB) PT Lowered to $3 at H.C. Wainwright
- Wall Street ends week positively; S&P 500, Dow hit record highs
- Bitcoin (BTC) Drops 3% as Turkey Bans Cryptocurrency Payments Citing Lack of Regulatory Supervision
- Morgan Stanley (MS) Archegos-Related Loss Appears to be $911M
- Dollar at 4-week low on retreating Treasury yields
- J&J (JNJ) Privately Asked Rival Covid-19 Vaccine Makers to Inspect Clotting Risks, AstraZeneca (AZN) Said Yes but Pfizer (PFE) and Moderna (MRNA) Declined - Report
H.C. Wainwright analyst Andrew Fein lowered the price target on Matinas BioPharma Holdings Inc. (NYSE: MTNB) to $3.00 (from $4.00) while maintaining a Buy rating.
You May Also Be Interested In
- Honda Motor Co Ltd (7267:JP) (HMC) PT Raised to JPY3,950 at Credit Suisse
- Seven Group Holdings Limited (SVW:AU) (SVNWF) PT Raised to AUD27.50 at Credit Suisse
- Tata Steel Ltd (TTST:LI) PT Raised to INR1,250 at JPMorgan
Create E-mail Alert Related CategoriesAnalyst PT Change
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!